Publicaciones

Vila A, Abal M, Muinelo-Romay L, Rodriguez-Abreu C, Rivas J, López-López R, Costa C. EGFR-Based Immunoisolation as a Recovery Target for Low-EpCAM CTC Subpopulation. PLoS One. 2016 Oct 6;11(10):e0163705. doi: 10.1371/journal.pone.0163705.
PMID: 27711186 IF: 3,7 Q1 Onco Clin

León-Mateos L, Vieito M, Anido U, López López R, Muinelo Romay L.
Clinical Application of Circulating Tumour Cells in Prostate Cancer: From Bench to Bedside and Back.
Int J Mol Sci. 2016 Sep 20;17(9). pii: E1580. IF: 3,2 Q2 BL

Rapado-González Ó, Majem B, Muinelo-Romay L, López-López R, Suarez-Cunqueiro MM. Cancer Salivary Biomarkers for Tumours Distant to the Oral Cavity. Int J Mol Sci. 2016 Sep 12;17(9). pii: E1531. doi: 10.3390/ijms17091531. IF: 3,2 Q2 BL

Mota A, Colás E, García-Sanz P, Campoy I, Rojo-Sebastián A, Gatius S, García Á, Chiva L, Alonso S, Gil-Moreno A, González-Tallada X, Díaz-Feijoo B, Vidal A, Ziober-Malinowska P, Bobi?ski M, López-López R, Abal M, Reventós J, Matias-Guiu X, Moreno-Bueno G. Genetic analysis of uterine aspirates improves the diagnostic value and captures the intra-tumor heterogeneity of endometrial cancers. Mod Pathol. 2016 Sep 2. doi: 10.1038/modpathol.2016.143. [Epub ahead of print] IF:6,3 D1 BL

Moran S, Martínez-Cardús A, Sayols S, Musulén E, Balañá C, Estival-Gonzalez A, Moutinho C, Heyn H, Diaz-Lagares A, de Moura MC, Stella GM, Comoglio PM, Ruiz-Miró M, Matias-Guiu X, Pazo-Cid R, Antón A, Lopez-Lopez R, Soler G, Longo F, Guerra I, Fernandez S, Assenov Y, Plass C, Morales R, Carles J, Bowtell D, Mileshkin L, Sia D, Tothill R, Tabernero J, Llovet JM, Esteller M.
Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis.
Lancet Oncol. 2016 Oct;17(10):1386-1395. doi: 10.1016/S1470-2045(16)30297-2. PMID: 27575023 IF 24,7 D1 EPI

Folprecht G, Pericay C, Saunders MP, Thomas A, Lopez Lopez R, Roh JK, Chistyakov V, Höhler T, Kim JS, Hofheinz RD, Ackland SP, Swinson D, Kopp M, Udovitsa D, Hall M, Iveson T, Vogel A, Zalcberg JR. Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study.
Ann Oncol. 2016 Jul;27(7):1273-9. doi: 10.1093/annonc/mdw176. PMID:27091810 IF 6,5 D1 Onco Clin

Roel M, Rubiolo JA, Guerra-Varela J, Silva SB, Thomas OP, Cabezas-Sainz P, Sánchez L, López R, Botana LM.
Marine guanidine alkaloids crambescidins inhibit tumor growth and activate intrinsic apoptotic signaling inducing tumor regression in a colorectal carcinoma zebrafish xenograft model. Oncotarget. 2016 Nov 4. doi: 10.18632/oncotarget.13068.[Epub ahead of print]
PMID:27825113 IF: 6.35, Q1 Cancer Modeling

González-Martín A, Alba E, Ciruelos E, Cortés J, Llombart A, Lluch A, Andrés R, Álvarez I, Aramendía JM, de la Peña FA, Barnadas A, Batista N, Calvo L, Galve E, García-Palomo A, García-Sáenz JÁ, de la Haba J, López R, López-Vivanco G, Martínez-Jáñez N, de Dueñas EM, Plazaola A, Rodríguez-Lescure Á, Ruiz M, Sánchez-Rovira P, Santaballa A, Seguí MÁ, Tusquets I, Zamora P, Martín M.
Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile.
Curr Cancer Drug Targets. 2016;16(5):415-28. Review IF 1,7 Oncol Clin

Alonso-Nocelo M, Abuín C, López-López R, de la Fuente M. Development and characterization of a three-dimensional co-culture model of tumor T cell infiltration. Biofabrication. 2016 Apr 14;8(2):025002. doi: 10.1088/1758-5090/8/2/025002. PMID:27078888 IF 4,3 D1 Cancer Model

Espinosa E, Soriano V, Malvehy J, Berrocal A, Martínez de Prado P, Quindós M, Soria A, Márquez-Rodas I, Palacio I, Cerezuela P, López-Vivanco G, Alonso L, Samaniego E, Ballesteros A, Puértolas T, Díaz-Beveridge R, de la Cruz-Merino L, López Castro R, López López R, Stevinson K, Del Barrio P, Tornamira MV, Guillém V, Martín-Algarra S. Treatment patterns of adjuvant interferon-?2b for high-risk melanoma: a retrospective study of the Grupo Español Multidisciplinar de Melanoma – Prima study.
Melanoma Res. 2016 Jun;26(3):278-83. doi: 10.1097/CMR.0000000000000254. PMID:26958991 IF 2,1 Q2 Oncol Clin

Moran S, Martínez-Cardús A, Sayols S, Musulén E, Balañá C, Estival-Gonzalez A, Moutinho C, Heyn H, Diaz-Lagares A, de Moura MC, Stella GM, Comoglio PM, Ruiz-Miró M, Matias-Guiu X, Pazo-Cid R, Antón A, Lopez-Lopez R, Soler G, Longo F, Guerra I, Fernandez S, Assenov Y, Plass C, Morales R, Carles J, Bowtell D, Mileshkin L, Sia D, Tothill R, Tabernero J, Llovet JM, Esteller M.
Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis.
Lancet Oncol. 2016 Oct;17(10):1386-1395. doi: 10.1016/S1470-2045(16)30297-2. PMID:27575023 IF 24,7 D1 Oncol Clin

Lorenzo-López L, López-López R, Maseda A, Diego-Díez C, Gómez-Caamaño S, Millán-Calenti JC. Prevalence and Clinical Characteristics of Prefrailty in Elderly Adults: Differences According to Degree of Urbanization. J Am Geriatr Soc. 2016 Jan;64(1):221-3. doi. PubMed PMID: 26782886. IF:4.57, D1 Oncol Clin

De Las Peñas R, Ponce S, Henao F, Camps Herrero C, Carcereny E, Escobar Álvarez Y, Rodríguez CA, Virizuela JA, López López R. SIADH-related hyponatremia in hospital day care units: clinical experience and management with tolvaptan. Support Care Cancer. 2016 Jan;24(1):499-507. PMID: 26431960; 2015. IF: 2.33, Q1 Oncol Cin

De Las Peñas R, Ponce S, Henao F, Camps Herrero C, Carcereny E, Escobar Álvarez Y, Rodríguez CA, Virizuela JA, López López R. SIADH-related hyponatremia in hospital day care units: clinical experience and management with tolvaptan. Support Care Cancer. 2016 Jan;24(1):499-507. PMID: 26431960; 2015. IF: 2.33, Q1 Oncol Clin

Crujeiras AB, Cabia B, Carreira MC, Amil M, Cueva J, Andrade S, Seoane LM, Pardo M, Sueiro A, Baltar J, Morais T, Monteiro MP, Lopez-Lopez R, Casanueva FF. Secreted factors derived from obese visceral adipose tissue regulate the expression of breast malignant transformation genes. Int J Obes (Lond). 2015 Oct 26. doi: 10.1038/ijo.2015.208. [Epub ahead of print] PubMed PMID: 26443342. IF: 5, D1 Oncol Mol

Cordeiro AS, Alonso MJ, de la Fuente M*. Nanoengineering of vaccines using natural polysaccharides. Biotechnology Advances (doi: 10.1016/j.biotechadv.2015.05.010). ISSN: 0734-9750 IF:8,905, D1 Nano

Reimondez-Troitiño S, Csaba N, Alonso MJ, de la Fuente M*. Nanotherapies for the treatment of ocular diseases. European Journal of Pharmaceutics and Biopharmaceutics. In Press (doi:10.1016/j.ejpb.2015.02.019). ISSN: 0939-6411.IF: 4,245, Q1 Nano

Seoane S, Arias E, Sigueiro R, Sendon-Lago J, Martinez-Ordoñez A, Castelao E, Eiró N, Garcia-Caballero T, Macia M, Lopez-Lopez R, Maestro M, Vizoso F, Mouriño A, Perez-Fernandez R. Pit-1 inhibits BRCA1 and sensitizes human breast tumors to cisplatin and vitamin D treatment. Oncotarget. 2015 Jun 10;6(16):14456-71. PubMed PMID: 25992773; PubMed Central PMCID: PMC4546479. IF: 6.35, Q1 Oncol Clin

De la Fuente M, Jones MC, Santander-Ortega MJ, Mirenska A, Marimuthu P, Uchegbu I, Schatzlein A*. A nano-enabled cancer-specific ITCH RNAi chemotherapy booster for pancreatic cancer. Nanomedicine- Nanotechnology, Biology and Medicine, 11(2):369-77, 2015. ISSN: 1549-9634. IF: 5,978, D1 Nano

Martínez-Lago N, Vieito-Villar M, Vidal-Insua Y, Padin-Iruegas ME, Vazquez-Rivera F, Candamio-Folgar S, Lopez-Lopez R. Adjuvant treatment with infusional 5-fluorouracil in high risk adenocarcinoma of the stomach or gastroesophageal junction. Clin Transl Oncol. 2015 Nov;17(11):856-61. doi: 10.1007/s12094-015-1314-y. Epub 2015 Jul 2. PubMed PMID: 26133519. IF: 2.07, Q3 Oncol Clin

De Castro Carpeño J, Gascón-Vilaplana P, Tejerina AM, Antón-Torres A, López-López R, Barnadas-Molins A, Cruz-Hernández JJ, Massuti-Sureda B, Camps-Herrero C, Aranda-Aguilar E, Laserna FJ. Epidemiology and characteristics of febrile neutropenia in oncology patients from Spanish tertiary care hospitals: PINNACLE study. Mol Clin Oncol. 2015 May;3(3):725-729. Epub 2015 Mar 5. PubMed PMID: 26137294; PubMed Central PMCID: PMC4471542. IF: 3.025 Q1 Oncol clin

Nieto D, Couceiro R, Aymerich M, Lopez-Lopez R, Abal M, Flores-Arias MT. Laser-based technology for fabricating a soda-lime glass based microfluidic device for circulating tumour cell capture. Colloids Surf B Biointerfaces. 2015 Oct 1;134:363-9. doi: 10.1016/j.colsurfb.2015.07.007. Epub 2015 Jul 11. PubMed PMID: 26218523. IF: 4.14, Q1 LB

de la Fuente A, Alonso-Alconada L, Costa C, Cueva J, Garcia-Caballero T,Lopez-Lopez R, Abal M. M-Trap: Exosome-Based Capture of Tumor Cells as a New Technology in Peritoneal Metastasis. J Natl Cancer Inst. 2015 Jul 6;107(9). pii: djv184. doi: 10.1093/jnci/djv184. Print 2015 Sep. PubMed PMID: 26150590. IF: 12.58 D1 Cancer Modeling

Bande MF, Santiago M, Muinelo-Romay L, Blanco MJ, Mera P, Capeans C, Pardo M, Piñeiro A. Detection of circulating melanoma cells in choroidal melanocytic lesions. BMC Res Notes. 2015 Sep 17;8:452. doi: 10.1186/s13104-015-1420-5. PubMed PMID: 26383622; PubMed Central PMCID: PMC4574067. LB

Campos Balea B, Sáenz de Miera Rodríguez A, Antolín Novoa S, Quindós Varela M, Barón Duarte F, López López R. [Venous thrombosis of atypical location in patients with cancer]. Med Clin (Barc). 2015 Jan;144 Suppl 1:38-40. doi:10.1016/S0025-7753(15)30017-8. Spanish. PubMed PMID: 25771091. Oncol Clin

Herranz M, Padín-Iruegas ME, Martínez-Lago N, Losada SA, Raña-Díez P, Vázquez EB, Carrera JJ, Antúnez JR, Ruibal A, López-López R. HIN-1: a New Epigenetic Biomarker Crucial for Therapy Selection in Glioblastoma Multiforme. Mol Neurobiol. 2015 Neuroscience DOI 10.1038/ijo.2015.208. IF: Q1, D3 Oncol Mol

Aznar N, Midde KK, Dunkel Y, Lopez-Sanchez I, Pavlova Y, Marivin A, Barbazán J, Murray F, Nitsche U, Janssen KP, Willert K, Goel A, Abal M, Garcia-Marcos M, Ghosh P. Daple is a novel non-receptor GEF required for trimeric G protein activation in Wnt signaling. Elife. 2015 Jun 30;4:e07091. doi: 10.7554/eLife.07091. PubMed PMID: 26126266; PubMed Central PMCID: PMC4484057.IF:9.3, D1 Oncol Mole

Pedrola N, Devis L, Llauradó M, Campoy I, Martinez-Garcia E, Garcia M, Muinelo-Romay L, Alonso-Alconada L, Abal M, Alameda F, Mancebo G, Carreras R, Castellví J, Cabrera S, Gil-Moreno A, Matias-Guiu X, Iovanna JL, Colas E, Reventós J, Ruiz A. Nidogen 1 and Nuclear Protein 1: novel targets of ETV5 transcription factor involved in endometrial cancer invasion. Clin Exp Metastasis. 2015 Jun;32(5):467-78. doi: 10.1007/s10585-015-9720-7. Epub 2015 Apr 30. PubMed PMID: 25924802. IF: 3.49, Q1 Oncol Mol

Alonso-Alconada L, Muinelo-Romay L, Madissoo K, Diaz-Lopez A, Krakstad C, Trovik J, Wik E, Hapangama D, Coenegrachts L, Cano A, Gil-Moreno A, Chiva L, Cueva J, Vieito M, Ortega E, Mariscal J, Colas E, Castellvi J,Cusido M, Dolcet X, Nijman HW, Bosse T, Green JA, Romano A, Reventos J, Lopez-Lopez R, Salvesen HB, Amant F, Matias-Guiu X, Moreno-Bueno G, Abal M; ENITEC Consortium. Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer. Mol Cancer. 2014, 27;13(1) 223. IF: 5,13 Q1 Oncol Mol

Alonso-Alconada L, Eritja N, Muinelo-Romay L, Barbazan J, Lopez-Lopez R, Matias-Guiu X, Gil-Moreno A, Dolcet X, Abal M. ETV5 transcription program links BDNF and promotion of EMT at invasive front of endometrial carcinomas. Carcinogenesis. 2014 .IF 5,63, Q1 Oncol Mol

Alonso-Alconada L, Santacana M, Garcia-Sanz P, Muinelo-Romay L, Colas E, Mirantes C, Monge M, Cueva J, Oliva E, Soslow RA, Lopez MA, Palacios J, Prat J, Valls J, Krakstad C, Salvesen H, Gil-Moreno A, Lopez-Lopez R, Dolcet X, Moreno-Bueno G, Reventos J, Matias-Guiu X, Abal M. Annexin-A2 as predictor biomarker of recurrent disease in endometrial cancer. Int J Cancer. 2014. IF 6,2 Q1 Oncol Mol

Costa C, Abal M, López-López R*, Muinelo-Romay L*.Biosensors for the Detection of Circulating Tumour Cells. Sensors (Basel). 2014 4(3): 4856-75. IF 1,9 Q1 BL

Reguera-Nuñez E, Roca C , Hardy E, de la Fuente M , Csaba N, Garcia-Fuentes M*. Implantable controlled release devices for BMP-7 delivery and suppression of glioblastoma initiating cells . Biomaterials, 35 (9): 2859–2867, 2014. ISSN: 0124-9612 IF: 8,312, D1 Cancer Modeling

Barbazán J, Muinelo-Romay L, Vieito M, Candamio S, Díaz-López A, Cano A, Gómez-Tato A, de Los Ángeles Casares de Cal M, Abal M, López-López R. A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer. Int J Cancer. 2014. IF 6,2 Q1 BL

Muinelo-Romay L, Vieito M, Abalo A, Nocelo MA, Barón F, Anido U, Brozos E, Vázquez F, Aguín S, Abal M, López RL. Evaluation of Circulating Tumor Cells and Related Events as Prognostic Factors and Surrogate. Biomarkers in Advanced¨ NSCLC Patients Receiving First-Line Systemic Treatment. Cancers (Basel). 2014, 6(1) 153-65 BL

Santander-Ortega MJ, de la Fuente M, Lozano MJ, Tsui ML, Bolton K, Uchegbu IF, Schätzlein A*. Optimisation of Synthetic Vector Systems for Cancer Gene Therapy – The Role of the Excess of Cationic Dendrimer Under Physiological Conditions. Current Topics in Medicinal Chemistry, 14: 1172-1181, 2014. ISSN: 1873-5294 Índice de impacto (ISI-JCR2013): 3,453. Q1 Oncol Mol

Muinelo-Romay L, Garcia D, Alonso-Alconada L, Vieito M, Carmona M, Martínez N, Aguín S, Abal M, López-López R. Zoledronic acid as an antimetastatic agent for different human tumor cell lines. Anticancer Res. 2013 33(12) 5295-300. FI:1.7 Q3 Oncol Mol

Gonzalez-Barcala FJ, Falagan JA, Garcia-Prim JM, Valdes L, Carreira JM, Puga A, Martín-Lancharro, P, Garcia-Sanz MT, Anton-Sanmartin D, Canive-Gomez JC, Pose-Reino A, Lopez-Lopez R. Timeliness of care and prognosis in patients with lung cancer. Ir J Med Sci. 2013. FI: 0.50 Q3 Oncol Clin

Jolis L, Carabantes F, Pernas S, Cantos B, López A, Torres P, Funes C, Caballero D, Benedit P, Salar A; PRAXIS Study Group. Incidence of chemotherapy-induced neutropenia and current practice of prophylaxis with granulocyte colony-stimulating factors in cancer patients in Spain: a prospective, observational study. Eur J Cancer Care (Engl). 2013 22(4) PAG513-21 FI: 1,3, Q1 Oncol Clin

Padín-Iruegas ME, Herranz-Carnero M, Aguin-Losada S, Brozos-Vazquez E, Anido-Herranz U, Antunez, Lopez JR, Ruibal-Morell A, López-López R. Prognostic value of changes in the expression of stem cell markers in the peripheral blood of patients with colon cancer. Oncol Rep. 2013. 29 2467-72. FI: 2,3 ,Q3 BL

Karachaliou N, Costa C, Gimenez-Capitan A, Molina-Vila MA, Bertran-Alamillo J, Mayo C, Massuti B, Majem M, Carcereny E, Moran T, Sanchez JJ, Viteri S, Gasco A, Wannesson L, Souglakos J, Jimeno J, Rosell R; Spanish Lung Cancer Group. BRCA1, LMO4, and CtIP mRNA expression in erlotinib-treated non-small-cell lung cancer patients with EGFR mutations. J Thorac Oncol. 2013 8(3) 295-300. IF: 4,4, Q1 Oncol Clin

González-Gómez P, Crecente-Campo J, Zahonero C, de la Fuente M, Hernández-Laín A, Mira H*, Sánchez-Gómez P*, Garcia-Fuentes M*. Controlled release microspheres loaded with BMP7 suppress primary tumors from human glioblastoma. Oncotarget, 6(13):1950-10963, 2015. ISSN: 1949-2553 2013 JCR Science Edition IF: 6,627, D1 NANO

Cruz IN, Zhang Y, de la Fuente M, Schätzlein A, Yang M*. Functional characterization of heat shock protein 90 targeted compounds. Analytical biochemistry, 438 (2): 107-109, 2013. ISSN: 0003-2697. IF (ISI-JCR2013): 2,305. Q2 NANo

Rahman KM, Jackson PJM, James CH, Basu P, Hartley JA, de la Fuente M, Schatzlein A, Robson M, Pedley B, Pepper C, Fox KR, Howard PW, Thurston DE*. GC-Targeted C8-linked Pyrrolobenzodiazepine (PBD)-Biaryl Conjugates with Femptomolar In Vitro Cytotoxicity and In Vivo Activity in Mouse Models. Journal of Medicinal Chemistry, 56 (7): 2911-2935, 2013. ISSN: 0022-2623. IF (ISI-JCR2013): 5,480. D1 NANO

Welsh SJ, Dale AG, Lombardo CM, de la Fuente M, Schätzlein A, Neidle S*. Inhibition of the hypoxia-inducible factor pathway by a G-quadruplex binding small molecule. Scientific Reports, 3:279 (1-9), 2013. ISSN: 2045-2322. IF (ISI-JCR2013): 5,078, D1 Oncol Mol

Mesía R, Rueda A, Vera R, Lozano A, Medina JA, Aguiar D, Arias F, Triana G, Carles J, López-López R. Adjuvant therapy with cetuximab for locally advanced squamous cell carcinoma of the oropharynx: results from a randomized, phase II prospective trial. Ann Oncol. 2012 IF: 7,38 D1 Oncol Clin

Carlos Gómez-Martin, Antonio Sánchez. Antonio Irigoyen, Beatriz Llorente, Begoña Pérez, Raquel Serrano, Mª José Safont, Esther Falcó, Adelaida Lacasta, Margarita Reboredo, Jorge Aparicio, Rosario Dueñas, Marta Llanos Muñoz, Pilar Regueiro, Elena Sanchez-Viñes, Rafael López López. Incidence of hand–foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen. Clin Transl Oncol. 2012 14 (9) 689-97 IF: 1.27 Q4 Oncol Clin

Lamas MJ, Duran G, Balboa E, Bernardez B, Candamio S, Vidal Y, Mosquera A, Giraldez JM, Lopez R, Carracedo A, Barros F. The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecanbased regimens. Cancer Chemother Pharmacol. 2012 69(6) 1591-9. IF:2,8 Q2 Oncol Clin

Fernandez-Rozadilla C, Cazier JB, Moreno V, Crous-Bou M, Guinó E, Durán G, Lamas MJ, López R, andamio S, Gallardo E, Paré L, Baiget M, Páez D, López-Fernández LA, Cortejoso L, García MI, Bujanda L, González D, Gonzalo V, Rodrigo L, Reñé JM, Jover R, Brea-Fernández A, Andreu M, Bessa X, Llor X, Xicola R, Palles C, Tomlinson I, Castellví-Bel S, Castells A, Ruiz-Ponte C, Carracedo A. Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5- fluorouracil or FOLFOX administration. Pharmacogenomics J. 2012. IF: 5,1 D1 Oncol Clin

Crujeiras AB, Cueva J, Vieito M, Curiel T, López-López R, Pollán M, Casanueva FF. Association of breast cancer and obesity in a homogeneous population from Spain. J Endocrinol Invest. 2012 35(7) 681-5. IF: 1.56, Q3 Oncol Clin

Barbazán, J., Alonso-Alconada, L., Muinelo-Romay, L., Vieito, M., Abalo, A., Alonso-Nocelo, M., Candamio, S., Gallardo, G., Fernández, B., Abdulkader, I., Casares, M.A., Gómez-Tato, A., López-López, R., Abal, M. Molecular Characterisation of Circulating Tumor Cells in Human Metastatic Colorectal Cancer. PlosOne 2012 7 (7) IF: 3,7 Q1 BL

López RL, Del Muro XG. Management of localized gastrointestinal stromal tumors and adjuvant therapy with imatinib. Anticancer Drug 2012 23 S3-6 IF: 2,4 Q2 Oncol Clin

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F et al.; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012 13(3) 239-46. IF: 25,1 D1 Oncol Clin

Khondaker R, Rosado H, Joao M, Feuerbaum E-A, Fox KR, Stecher E, Howard PW, Gregson SJ, James CH, de la Fuente M, Waldron DN, Thurston DE, Taylor PW*. Anti-staphylococcal activity of DNA unteractive pyrrolobenzodiazepine (PBD) dimers and PBD-biaryl conjugates. Journal of Antimicrobial Chemotherapy, 67 (7): 1683-1696, 2012. ISSN: 0305-7453. IF (ISI-JCR2012): 5.388. D1 Oncol Mol

de la Fuente M*, Raviña M, Fernández-Megía E, Correa J, Sousa-Hervés A, Riguera R, Sánchez A, Alonso MJ. Exploring the efficiency of gallic acid-based dendrimers as carriers in gene delivery. Nanomedicine, 7 (11): 1667-1681, 2012. ISSN: 1742-5889. IF (ISI-JCR2012): 5.055 D1 NANO

Barbazán J, Vieito M, Abalo A, Alonso-Alconada L, Muinelo-Romay L, Alonso-Nocelo M, León L, Candamio S, Gallardo E, Anido U, Doll A, de Los Ángeles Casares M, Gómez-Tato A, Abal M, López-López R. A logistic model for the detection of circulating tumor cells in human metastatic colorectal cancer. J Cell Mol Med. 2012 Feb 3. 16(10) 2342-9 IF: 4,7 Q1 BL

Colas, E., Muinelo-Romay, L., Alonso-Alconada, L., Llaurado, M., Monge, M., Barbazan, J., Gonzalez, M., Schoumacher, M., Pedrola, N., Ertekin, T., Devis, L., Ruiz, A., Castellvi, J., Doll, A., Gil-Moreno, A., Vazquez- Levin, M., Lapyckyj, L., Lopez-Lopez, R., Robine, S., Friederich, E., Castro, M., Reventos, J., Vignjevic, D., Abal M. ETV5 cooperates with LPP as a sensor of extracellular signals and promotes EMT in endometrial carcinomas. Oncogene 2012 31(45) 4778-88 IF: 7,4 D1 Oncol Mol

Juan F. Cueva, Marcos Calvo, Urbano Anido, Luis León, Elena Gallardo, Carmen Areses, Beatriz Bernárdez, Lucía Gayoso, Jorge García, María Jesús Lamas, Teresa Curiel, Francisca Vázquez, Sonia Candamio, Yolanda Vidal, Francisco Javier Barón, Rafael López. Methylphenidate in the management of asthenia in breast cancer patients treated with docetaxel: results of a pilot study. Invest New Drugs 2012 30(2) 688-94 IF: 3.5 Q1 Oncol Clin

Santander-Ortega MJ, de la Fuente M, Lozano MV, Bekheet ME, Progatzky F, A. Elouzi, Uchegbu IF, Schätzlein AG*. Hydration forces as a tool for the optimization of core–shell nanoparticle vectors for cancer gene therapy. Soft Matter, 8: 12080-12092, 2012. ISSN: 1744-683X IF (ISI-JCR2012): 3.909. D1 NANO

Veiga R, Durán G, Lamas MJ, Cueva JF, Bernardez B, Curiel T, López R. Practice pattern for patients eceiving bevacizumab in metastatic breast cancer. J clin oncol 2011, 29. IF: 1,7 Q3 Oncol Clin

Viñolas N, Provencio M, Reguart N, Cardenal F, Alberola V, Sánchez-Torres JM, Barón FJ, Cobo M, Maestu I, Moreno I, Mesía C, Izquierdo A, Felip E, López-Brea M, Márquez A, Sánchez-Ronco M, Tarón M, Santarpia MC, Rosell R; Spanish Lung Cancer Group. Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine. REVISTA Lung Cancer2011 71(2) 191-8 IF:3,4 Q1 Oncol Clin

G. Duran, M.J. Lamas, M. Iglesias, B. Bernardez, J.M. Giraldez, S. Candamio, Y.Vidal, R. Lopez, A. Carracedo, F. Barros. Explore the Role That DMET Genotyplng Platform May Play in Search of Genetic Polymorphism Associated With Severe Toxicity. EUR. J. CANCER. 2011 47 IF: 5,06 Q1 Oncol Mol

Muinelo-Romay L, Colas E, Barbazan J, Alonso-Alconada L, Alonso-Nocelo M, Bouso M, Curiel T, Cueva J, Anido U, Forteza J,Gil-Moreno A, Reventos J, Lopez-Lopez R, Abal M. High-risk endometrial carcinoma profiling identifies TGF-Beta1 as a key factor in the initiation of tumor invasion. Mol Cancer Ther. 2011 10(8) 1357-66 IF: 5,5 Q1 Cancer Modeling

Areses MC, Herranz UA, Ferrán BB, Mateos LL, González JG, López RL. Temsirolimus in renal cell carcinoma with sarcomatoid differentiation: a report of three cases. Med Oncol. 2011 29 (2) 795-8 IF: 2,1 Q3 Oncol Clin

Colas E, Perez C, Cabrera S, Pedrola N, Monge M, Castellvi J, Eyzaguirre F, Gregorio J, Ruiz A, Llaurado M, Rigau M, Garcia M, Ertekin T, Montes M, Lopez-Lopez R, Carreras R, Xercavins J, Ortega A, Maes T, Rosell E, Doll A, Abal M, Reventos J, Gil-Moreno A. Molecular markers of endometrial carcinoma detected in uterine aspirates. Int J Cancer. 2011 2129(10) 2435-44 IF: 6,2 Q1 Oncol Mol

Lamas MJ, Duran G, Balboa E, Bernardez B, Touris M, Vidal Y, Gallardo E, Lopez R, Carracedo A, Barros F. Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer. Pharmacogenomics. 2011 12 (3) 433-42 IF: 3,8 Q1 Oncol Clin

Contreras-Ruiz L, de la Fuente M, Párraga J, López-García A, Fernández I, Seijo B, Sánchez A, Calonge M, Diebold Y*. Intracellular trafficking of hyaluronic acid-chitosan oligomer- based nanoparticles in cultured human ocular surface cells. Molecular Vision, 17: 279-290, 2011. ISSN: 1090-0535.IF (ISI-JCR2011): 2.205. Q2 NANO

Gunaratnam M, de la Fuente M, Hampel SM, Todd AK, Reszka AP, Schatzlein A, Neidle S*. Targeting pancreatic cancer with a G-quadruplex ligand, Bioorganic & Medicinal Chemistry 19 (23): 7151-7157, 2011. ISSN: 0968-0896 IF (ISI-JCR2011): 2.921 Q2 Oncol Mol

Patel SM, de la Fuente M, Ke S, Guimarães AMR, Oliyide AO, Ji X, Stapleton P, Osbourn A, Pan Y, Bowles DJ, Davis BJ, Schatzlein AS, Yang M*. High throughput discovery of heteroaromatic-modifying enzymes allows enhancement of novobiocin selectivity. Chemical Communications,47: 10569-10571, 2011. ISSN: 1359-7345 IF (ISI-JCR2011): 6.169 – Q1 Oncol Mol

Lamas MJ, Duran G, Gomez A, Balboa E, Anido U, Bernardez B, Rana-Diez P, Lopez R, Carracedo A, Barros F. X-Ray Cross-Complementing Group 1 and Thymidylate Synthase Polymorphisms Might Predict Response to Chemoradiotherapy in Rectal Cancer Patients. Int J Radiat Oncol Biol Phys. 2011 82(1) 138-44 IF: 4,5 D1 Oncol Mol

Gómez A, Salgado M, Valladares-Ayerbes M, Jorge M, Carballo A, Candamio S, Izquierdo P, Peleteiro P, López R. Efficacy of epoetin-beta 30,000 IU/week in correcting anaemia in patients with gastrointestinal tumours subjected to concomitant chemoradiotherapy. Clin Transl Oncol 2010 12(12) 843-8 IF: 1,7 Q3 Oncol Clin

López R, Salgado M, Reboredo M, Grande C, Méndez JC, Jorge M, Romero C, Quintero G, de la Cámara J, Candamio S. A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer. Br J Cancer 2010 103(10) 1536-41 IF: 5,08 Q1 Oncol Clin

Felip E, Rosell R, Maestre JA, Rodríguez-Paniagua JM, Morán T, Astudillo J, Alonso G, Borro JM, González-Larriba JL, Torres A, Camps C, Guijarro R, Isla D, Aguiló R, Alberola V, Padilla J, Sánchez-Palencia A, Sánchez JJ, Hermosilla E, Massuti B; Spanish Lung Cancer Group. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. J Clin Oncol. 2010 1; 28(19) 3138-45. IF:18 D1 Oncol Clin

Gómez A, Salgado M, Valladares-Ayerbes M, Jorge M, Carballo A, Candamio S, Castro E, López R. Anemia response and safety to epoetin-beta treatment in patients with neoadjuvant therapy prior to primary digestive tract tumor surgery. Cancer Chemother Pharmacol 2010 66(3) 567-73 IF: 2,8 Q2 Oncol Clin

Calvo E, Maroto P, del Muro XG, Climent MA, González-Larriba JL, Esteban E, López R, Paz-Ares L, Bellmunt J, Castellano D Updated recommendations from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma. Cancer Metastasis Rev 2010 29 Suppl 1-10 IF: 7,78 D1 Oncol Clin

Balboa E, Duran G, Lamas MJ, Gomez-Caamaño A, Celeiro-Muñoz C, Lopez R, Carracedo A, Barros F. Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response. Pharmacogenomics 2010 11(6) 747-61 IF: 3,8 Q1 Oncol Mol

Feliu J, Safont MJ, Salud A, Losa F, García-Girón C, Bosch C, Escudero P, López R, Madroñal C, Bolaños M, Gil M, Llombart A, Castro-Carpeño J, González-Barón M. Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer. Br J Cancer 2010 102(10) 1468-73.IF: 5,08 Q1 Oncol Clin

Bellmunt J, Trigo JM, Calvo E, Carles J, Pérez-Gracia JL, Rubió J, Virizuela JA, López R, Lázaro M,Albanell J. Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06) Lancet Oncol 2010 11(4) 350-7. IF: 25,1 D1 Oncol Clin

de la Fuente, M. Raviña, P. Paolicelli, A. Sánchez, B. Seijo, MJ. Alonso*. Chitosan-based nanostructures: a delivery platform for ocular therapeutics. Advanced drug delivery reviews, 61: 110 – 117, 2010 ISSN: 0169-409X. IF: 13.557,D1 NANO

Contreras-Ruiz L, de la Fuente M, García-Vázquez C, Sáez V, Seijo B, Alonso MJ, Calonge M, Diebold Y*. Ocular tolerance to a topical formulation of hyaluronic acid and chitosan-based nanoparticles. Cornea, 29 (5): 550-558, 2010. ISSN: 0277-3740. IF I: 1.762, D2 NANO

Raviña M, de la Fuente M, Correa J, Sousa-Herves A, Pinto J, Fernandez-Megía E, Riguera R, Sánchez A, Alonso MJ*. Core-shell dendriplexes with Sterically Induced Stoichiometry for Gene Delivery. Macromolecules, 43 (17): 6953 -6961, 2010. ISSN: 0024- Oncol Mol

idis
logo-centro
frd